Info
🌱 來自: Huppert’s Notes
SGLT2 Inhibitors in Diabetic Kidney Disease🚧 施工中
SGLT2 Inhibitors in Diabetic Kidney Disease
• CREDENCE. N Eng J Med 2019;380(24):2295–2306.
- Prospective, double-blind, randomized controlled trial that randomized patients with DM2, albuminuria, and reduced GFR to the SGLT2 inhibitor canagliflozin or placebo. Canagliflozin 100 mg/day reduced risk of kidney failure and cardiovascular events among these patients.